The Oncology Institute, Inc.

Good afternoon, and welcome to the Oncology Institute's fourth quarter and full year 2024 earnings conference call. Today's call is being recorded, and we have allocated one hour for prepared remarks and questions and answers. At this time, I'd like to turn the conference over to Mark Hebelheiser, General Counselor at TOI. Thank you. You may begin.

The press release announcing the Oncology Institute's results for the fourth quarter and full year 2024 are available at the investor section of the company's website, theoncologyinstitute.com. A replay of this call will also be available at the company's website after the conclusion of this call. Before we get started, I would like to remind you of the company's safe harbor language included within the company's press release for the fourth quarter and full year 2024. Management may make forward-looking statements, including guidance and underlying assumptions. Forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. For a further discussion of risks related to our business, see our filings with the SEC. This call will also discuss non-GAAP financial measures, such as adjusted EBITDA and free cash flow. Reconciliation of these non-GAAP measures to the most comparable GAAP measures are included in the earnings release furnished to the SEC and available on our website. Joining me on the call today is our CEO, Dan Vernick, and our CFO, Rob Carter. Following our prepared remarks, we'll open the call for your questions.

With that, I'll turn the call over to Dan. Thank you, Mark. Good afternoon, everyone.